Outpatient percutaneous central venous access in cancer patients

Broadwater, J. R.; Henderson, Michael A.; Bell, John L.; Edwards, Michael J.; Smith, G. Jeffrey; McCready, David R.; Swanson, Richard S.; Hardy, Mark E.R.; Shenk, Robert; Lawson, Millie; Ota, David M.; Balch, Charles M.

doi:10.1016/s0002-9610(05)80773-1

Cited by 30 publications

(10 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patient education involving CVCs is described as an important factor in only a few non-randomized and non-controlled studies. [25][26][27][28][29] In particular, one study 29 described patient education as a key factor in a total quality management programme for bone marrow transplant (BMT) patients at the Thomas Hazen Transplant Center, Chicago. Over a period of one and a half years, data were collected on CRBSIs causing re-admissions following BMT, and compared with an intervention of increased patient education.…”

Section: Discussionmentioning

confidence: 99%

Patient education—a strategy for prevention of infections caused by permanent central venous catheters in patients with haematological malignancies: a randomized clinical trial

Møller¹,

Borregaard²,

Tvede³

et al. 2005

Journal of Hospital Infection

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Patient education—a strategy for prevention of infections caused by permanent central venous catheters in patients with haematological malignancies: a randomized clinical trial

Møller¹,

Borregaard²,

Tvede³

et al. 2005

Journal of Hospital Infection

View full text Add to dashboard Cite

“…99 Descriptive and prospective nonrandomized trials have reported a number of patient benefits, including no need for additional peripheral venipunctures, greater convenience, and arms left free for activities of daily living, whereas patients generally disliked the visibility of ports and complained about site soreness. 9,100 Clinical trials to evaluate safety, costs, and quality of life of central venous ports have been basically open-label, single-arm, Phase II studies [101][102][103] Vascular Access in Oncology Patients or comparative studies with externalized tunneled systems; they have provided little information on quality of life and global costs, especially when only prospective data are taken into consideration, 104,105 A paper from our group 64 has provided clinicians, health care planners, and funding agencies with data derived from a large prospective study on total cost of devices for long-term chemotherapy of solid tumors. Briefly, 333 port devices, amounting to a total of 79,178 days in situ, were placed during a 30-month period in 328 patients (5 patients underwent a second placement after removal of the first device), who were followed prospectively for a minimum of 180 days in order to detect device-related and overall complications.…”

Section: Patient Issues: Vascular Access and Quality Of Lifementioning

confidence: 99%

Vascular Access in Oncology Patients

Gallieni

Pittiruti

Biffi

2008

CA: A Cancer Journal for Clinicians

255

166

View full text Add to dashboard Cite

Adequate vascular access is of paramount importance in oncology patients. It is important in the initial phase of surgical treatment or chemotherapy, as well as in the chronic management of advanced cancer and in the palliative care setting. We present an overview of the available vascular access devices and of the most relevant issues regarding insertion and management of vascular access. Particular emphasis is given to the use of ultrasound guidance as the preferred technique of insertion, which has dramatically decreased insertion-related complications. Vascular access management has considerably improved after the publication of effective guidelines for the appropriate nursing of the vascular device, which has reduced the risk of late complications, such as catheter-related bloodstream infection. However, many areas of clinical practice are still lacking an evidence-based background, such as the choice of the most appropriate vascular access device in each clinical situation, as well as prevention and treatment of thrombosis. We suggest an approach to the choice of the most appropriate vascular access device for the oncology patient, based on the literature available to date. (CA Cancer J Clin 2008;58:323-346.)

show abstract

“…A rate of catheter-related colonization of 16% for both the benzalkonium chloride-impregnated and the standard catheters was observed in our study. Other studies have shown a broad range of up to 53% for the incidence of catheter-related infections in cancer patients [10,11]. Although the patients in our study had a very high risk of infectious complications due to severe neutropenia (!100/Ìl) [12], no benefit was demonstrable for patients in the study group.…”

Section: Discussionmentioning

confidence: 64%

Efficacy of a Benzalkonium Chloride-Impregnated Central Venous Catheter to Prevent Catheter-Associated Infection in Cancer Patients

Jaeger¹,

Osthaus²,

Heine³

et al. 2000

Chemotherapy

View full text Add to dashboard Cite

Background: This study was performed to determine the efficacy of a benzalkonium chloride-impregnated central venous catheter (CVC) in preventing catheter-related infection in patients suffering from malignant diseases and undergoing chemotherapy. Methods: A randomized, prospective clinical trial was carried out to compare the incidence of catheter-related colonization and catheter-related bacteremia using an antiseptic-impregnated CVC (n = 25) with that using a standard triple-lumen CVC (n = 25). Results: All patients were treated with intensive chemotherapy for acute leukemia (n = 28), lymphoma (n = 17) or solid tumors (n = 5). Both study groups presented with similar data in regards to age, insertion site, duration of catheterization and neutropenia period during catheterization, demonstrating a comparable risk for catheter-related colonization. Suspicion of infection led to explantation in 14 versus 15 cases. Catheter-related colonization was proven in 4 cases (16%) and catheter-related bacteremia was observed only once (4%) in both groups. Statistical testing showed no significant differences between the study and control group. Conclusions: The rate of catheter-related colonization was lower than suspected in this high-risk patient group. The use of benzalkonium chloride-impregnated CVC failed to decrease the incidence of catheter-related colonization and bacteremia in patients with a high risk of infectious complications.

show abstract

Outpatient percutaneous central venous access in cancer patients

Cited by 30 publications

References 11 publications

Patient education—a strategy for prevention of infections caused by permanent central venous catheters in patients with haematological malignancies: a randomized clinical trial

Patient education—a strategy for prevention of infections caused by permanent central venous catheters in patients with haematological malignancies: a randomized clinical trial

Vascular Access in Oncology Patients

Efficacy of a Benzalkonium Chloride-Impregnated Central Venous Catheter to Prevent Catheter-Associated Infection in Cancer Patients

Contact Info

Product

Resources

About